touchONCOLOGY touchONCOLOGY
Breast Cancer
Watch Time: 11 mins

Claudine Isaacs, SABCS 2022: Cemiplimab plus REGN3767 in HER2-negative breast cancer: The I-SPY2 trial

Copy Link
Published Online: Dec 22nd 2022

The I-SPY2 trial (NCT01042379) is a multicentre, phase 2 trial where patients with HER2-negative breast cancer were randomized to receive neoadjuvant cemiplimab plus REGN3767 and paclitaxel or weekly paclitaxel for 12 cycles. In this touchONCOLOGY interview, we speak with Prof. Claudine Isaacs (Georgetown University, Washington, DC, USA) who gives an overview of the I-SPY2 study with the rationale for the use of cemiplimab plus REGN3767 as well as discussing the aims, design and findings of the study.

The abstract entitled ‘Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.

Questions:

  1. Could you give us a brief overview of the I-SPY2 study? (0:20)
  2. What is the rationale for the use of cemiplimab and fianlimib in women with breast cancer? (1:11)
  3. What were the aims, design and eligibility criteria of this I-SPY 2 substudy? (3:27)
  4. What were the efficacy and safety findings of the study? (4:28)
  5. Which women are most likely to benefit from this regimen? (9:17)

Disclosures: Claudine Isaacs is a consultant for Genentech, PUMA, Seattle Genetics, AstraZeneca, Novartis, Pfizer, ESAI, Sanofi, ION and Gilead and discloses grant/research support from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech and Novartis.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen

Filmed as a highlight of SABCS 2022

Access more content on Breast Cancer

Related Videos In Breast Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72